It’s early days yet, but checkpoint immunotherapies have the potential to jump-start the high-risk, high reward glioblastoma drug development space, which has been prone to many a setback, the latest casualty being Celldex Therapeutics Inc.’s Rintega vaccine.
Checkpoint inhibitors, namely Bristol-Myers Squibb Co.’s Yervoy and Opdivo, Merck & Co. Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?